Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zeprumetostat in advanced malignant bone and soft tissue tumors (phase 2, single-arm)
ChiCTR2600128282Phase 2Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zeprumetostat in bone cancer and soft tissue sarcoma (STS), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Objective Response Rate (ORR), Progression-Free Survival (PFS) and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
zeprumetostat
03
Conditions
bone cancersoft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2600128282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128282.